Novo Nordisk filed the New Drug Application (NDA) for CagriSema in early 2026, based on positive results from the REDEFINE phase 3 trial program

Macromolecule Content Total Structure Weight: 525.75 kDa Atom Count: 34,893 Modeled Residue Count: 4,474 Deposited Residue Count: 4,824 Unique protein chains: 1 Experimental Data Method: X-RAY DIFFRACTION Resolution: 2.70 R-Value Free: 0.226 (Depositor), 0.227 (DCC) R-Value Work: 0.207 (Depositor), 0.208 (DCC) R-Value Observed: 0.208 (Depositor) Unit Cell : Software Package: Revision History (Full details and data files) Version 1.0: 2020-05-27 Type: Initial release Version 2.0: 2020-07-29 Type: Remediation Reason: Carbohydrate remediation Changes: Advisory, Atomic model, Data collection, Derived calculations, Structure summary Version 3.0: 2020-12-09 Type: Coordinate replacement Reason: Atomic clashes Changes: Advisory, Atomic model, Data collection, Database references, Derived calculations, Non-polymer description, Refinement description, Structure summary Version 3.1: 2020-12-16 Changes: Database references Version 3.2: 2024-05-15 Changes: Data collection, Database references, Refinement description

Discard vials according to recommended time based safety guidelines
An issuer may offer to purchase a structured note in the secondary market, but it is not required to do so
You can prevent and, to a certain extent, repair the damage they cause to your body, through a better lifestyle and nutrition
To find out more about B12 vitamin shots at IV Boost UK, call our team on 020 3095 0002.